Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sinusitis | 35 | 2023 | 187 | 12.570 |
Why?
|
Rhinitis | 32 | 2023 | 165 | 12.090 |
Why?
|
Paranasal Sinuses | 16 | 2022 | 63 | 4.890 |
Why?
|
Paranasal Sinus Neoplasms | 12 | 2022 | 53 | 4.660 |
Why?
|
Endoscopy | 26 | 2023 | 181 | 4.290 |
Why?
|
Nose Neoplasms | 11 | 2022 | 34 | 4.090 |
Why?
|
Nasal Polyps | 11 | 2023 | 62 | 4.040 |
Why?
|
Chronic Disease | 32 | 2023 | 495 | 3.450 |
Why?
|
Retrospective Studies | 55 | 2023 | 3273 | 2.790 |
Why?
|
Head and Neck Neoplasms | 10 | 2023 | 133 | 2.600 |
Why?
|
Humans | 118 | 2023 | 29337 | 2.320 |
Why?
|
Eosinophils | 4 | 2022 | 47 | 2.290 |
Why?
|
Esthesioneuroblastoma, Olfactory | 5 | 2020 | 11 | 2.120 |
Why?
|
Coronavirus Infections | 7 | 2020 | 86 | 2.110 |
Why?
|
Pneumonia, Viral | 7 | 2020 | 89 | 2.100 |
Why?
|
Betacoronavirus | 7 | 2020 | 75 | 2.080 |
Why?
|
Neoplasm Staging | 14 | 2021 | 340 | 2.080 |
Why?
|
Survival Rate | 18 | 2021 | 349 | 1.950 |
Why?
|
SEER Program | 11 | 2019 | 38 | 1.910 |
Why?
|
Middle Aged | 57 | 2023 | 9823 | 1.840 |
Why?
|
Eosinophilia | 5 | 2019 | 47 | 1.790 |
Why?
|
Female | 68 | 2021 | 16197 | 1.760 |
Why?
|
Male | 64 | 2021 | 15621 | 1.690 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 24 | 1.690 |
Why?
|
Clinical Laboratory Techniques | 3 | 2020 | 34 | 1.660 |
Why?
|
Nasal Mucosa | 3 | 2019 | 16 | 1.510 |
Why?
|
Nasal Cavity | 5 | 2020 | 35 | 1.460 |
Why?
|
Prognosis | 15 | 2021 | 840 | 1.380 |
Why?
|
Melanoma | 3 | 2021 | 52 | 1.330 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2022 | 178 | 1.310 |
Why?
|
Adult | 38 | 2023 | 8601 | 1.300 |
Why?
|
Laryngeal Neoplasms | 7 | 2023 | 30 | 1.250 |
Why?
|
Frontal Sinus | 2 | 2017 | 12 | 1.200 |
Why?
|
Sarcoma | 3 | 2021 | 65 | 1.130 |
Why?
|
Aged | 40 | 2023 | 9448 | 1.120 |
Why?
|
Treatment Outcome | 20 | 2023 | 3478 | 1.020 |
Why?
|
Age Factors | 8 | 2020 | 843 | 0.990 |
Why?
|
Adenocarcinoma | 3 | 2021 | 189 | 0.970 |
Why?
|
United States | 16 | 2021 | 2333 | 0.960 |
Why?
|
Nasal Surgical Procedures | 4 | 2019 | 8 | 0.960 |
Why?
|
Otolaryngology | 5 | 2021 | 27 | 0.950 |
Why?
|
Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 10 | 0.950 |
Why?
|
Intracranial Hypertension | 1 | 2023 | 14 | 0.940 |
Why?
|
Smell | 3 | 2020 | 18 | 0.940 |
Why?
|
Simulation Training | 2 | 2020 | 34 | 0.910 |
Why?
|
Nose | 8 | 2021 | 36 | 0.910 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 2 | 2020 | 2 | 0.890 |
Why?
|
Skull Base | 5 | 2023 | 26 | 0.860 |
Why?
|
Maxillary Sinus Neoplasms | 3 | 2020 | 6 | 0.860 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 138 | 0.810 |
Why?
|
Pandemics | 8 | 2020 | 236 | 0.800 |
Why?
|
Neutrophils | 2 | 2018 | 117 | 0.790 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 132 | 0.790 |
Why?
|
Postoperative Complications | 6 | 2022 | 957 | 0.790 |
Why?
|
Ethmoid Sinus | 2 | 2017 | 11 | 0.770 |
Why?
|
Nasopharynx | 1 | 2020 | 7 | 0.760 |
Why?
|
Laryngopharyngeal Reflux | 1 | 2020 | 2 | 0.760 |
Why?
|
Personnel, Hospital | 1 | 2020 | 17 | 0.760 |
Why?
|
Neoplasm Grading | 6 | 2021 | 45 | 0.750 |
Why?
|
Lacrimal Apparatus | 2 | 2017 | 2 | 0.750 |
Why?
|
Optical Imaging | 2 | 2017 | 7 | 0.740 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2020 | 4 | 0.740 |
Why?
|
Olfaction Disorders | 5 | 2021 | 53 | 0.740 |
Why?
|
Point-of-Care Testing | 1 | 2020 | 24 | 0.740 |
Why?
|
Reoperation | 3 | 2019 | 932 | 0.740 |
Why?
|
Voice Quality | 1 | 2019 | 5 | 0.710 |
Why?
|
Preoperative Care | 1 | 2020 | 135 | 0.710 |
Why?
|
Quality of Life | 4 | 2020 | 662 | 0.710 |
Why?
|
Maxillary Diseases | 1 | 2018 | 3 | 0.680 |
Why?
|
Insurance Coverage | 1 | 2019 | 13 | 0.680 |
Why?
|
Severity of Illness Index | 9 | 2021 | 1113 | 0.680 |
Why?
|
Prednisone | 1 | 2018 | 67 | 0.670 |
Why?
|
Registries | 2 | 2018 | 188 | 0.650 |
Why?
|
Osteoblastoma | 1 | 2018 | 3 | 0.650 |
Why?
|
Young Adult | 17 | 2020 | 1932 | 0.650 |
Why?
|
Adolescent | 17 | 2020 | 2279 | 0.640 |
Why?
|
Child | 13 | 2022 | 1346 | 0.640 |
Why?
|
Anti-Inflammatory Agents | 1 | 2018 | 100 | 0.640 |
Why?
|
Neoplasms, Second Primary | 1 | 2018 | 30 | 0.630 |
Why?
|
Olfactory Nerve | 1 | 2017 | 1 | 0.630 |
Why?
|
Olfactory Receptor Neurons | 1 | 2017 | 1 | 0.630 |
Why?
|
Tomography, X-Ray Computed | 8 | 2022 | 770 | 0.630 |
Why?
|
Therapeutic Irrigation | 1 | 2017 | 66 | 0.610 |
Why?
|
Respiratory Tract Diseases | 1 | 2017 | 6 | 0.600 |
Why?
|
Desensitization, Immunologic | 1 | 2017 | 5 | 0.600 |
Why?
|
Stents | 1 | 2017 | 76 | 0.590 |
Why?
|
Frontal Sinusitis | 1 | 2016 | 3 | 0.580 |
Why?
|
Patient Reported Outcome Measures | 1 | 2020 | 379 | 0.570 |
Why?
|
Dissection | 1 | 2016 | 27 | 0.570 |
Why?
|
Biofilms | 1 | 2016 | 15 | 0.560 |
Why?
|
Aspirin | 1 | 2017 | 83 | 0.560 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 107 | 0.560 |
Why?
|
Tongue Neoplasms | 3 | 2021 | 16 | 0.550 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 3 | 2021 | 28 | 0.550 |
Why?
|
Combined Modality Therapy | 4 | 2021 | 364 | 0.550 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 90 | 0.550 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 184 | 0.540 |
Why?
|
Nose Diseases | 1 | 2015 | 8 | 0.540 |
Why?
|
Databases, Factual | 6 | 2021 | 330 | 0.510 |
Why?
|
Inflammation | 4 | 2023 | 344 | 0.510 |
Why?
|
Cochlear Implantation | 2 | 2010 | 22 | 0.470 |
Why?
|
Risk Factors | 10 | 2021 | 2443 | 0.470 |
Why?
|
Carcinoma | 3 | 2020 | 57 | 0.470 |
Why?
|
Temporal Bone | 2 | 2010 | 10 | 0.460 |
Why?
|
Tertiary Care Centers | 4 | 2020 | 65 | 0.450 |
Why?
|
Encephalocele | 2 | 2023 | 26 | 0.440 |
Why?
|
Prospective Studies | 7 | 2023 | 1811 | 0.440 |
Why?
|
Neck Dissection | 3 | 2021 | 17 | 0.430 |
Why?
|
Glossitis | 1 | 2011 | 1 | 0.420 |
Why?
|
Mometasone Furoate | 2 | 2022 | 6 | 0.420 |
Why?
|
Sutures | 1 | 2011 | 41 | 0.410 |
Why?
|
Pituitary Neoplasms | 3 | 2020 | 20 | 0.400 |
Why?
|
Abscess | 1 | 2011 | 26 | 0.400 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 81 | 0.400 |
Why?
|
Cochlear Implants | 2 | 2010 | 30 | 0.390 |
Why?
|
Aged, 80 and over | 14 | 2021 | 4851 | 0.390 |
Why?
|
Smoking | 3 | 2020 | 194 | 0.380 |
Why?
|
Incidence | 7 | 2019 | 756 | 0.380 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2010 | 16 | 0.380 |
Why?
|
Speech Perception | 2 | 2010 | 48 | 0.380 |
Why?
|
Preoperative Period | 3 | 2019 | 65 | 0.380 |
Why?
|
Rhinoplasty | 3 | 2023 | 11 | 0.360 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2010 | 32 | 0.360 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2010 | 46 | 0.360 |
Why?
|
Cohort Studies | 7 | 2020 | 1939 | 0.360 |
Why?
|
Follow-Up Studies | 6 | 2020 | 1830 | 0.360 |
Why?
|
Leukocyte Count | 2 | 2019 | 92 | 0.350 |
Why?
|
Laryngectomy | 4 | 2023 | 17 | 0.350 |
Why?
|
Rhinitis, Allergic | 2 | 2020 | 24 | 0.340 |
Why?
|
Wound Healing | 2 | 2020 | 168 | 0.340 |
Why?
|
Cerebrospinal Fluid Leak | 3 | 2023 | 18 | 0.340 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 389 | 0.330 |
Why?
|
Telemedicine | 2 | 2020 | 99 | 0.330 |
Why?
|
Disease Management | 2 | 2020 | 114 | 0.310 |
Why?
|
Survival Analysis | 5 | 2021 | 298 | 0.310 |
Why?
|
Salvage Therapy | 3 | 2023 | 36 | 0.310 |
Why?
|
Recurrence | 3 | 2018 | 350 | 0.310 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2020 | 52 | 0.300 |
Why?
|
Child, Preschool | 6 | 2016 | 642 | 0.300 |
Why?
|
Internship and Residency | 2 | 2021 | 211 | 0.300 |
Why?
|
Chicago | 2 | 2020 | 865 | 0.300 |
Why?
|
Margins of Excision | 3 | 2021 | 17 | 0.280 |
Why?
|
Cadaver | 2 | 2017 | 359 | 0.280 |
Why?
|
Postoperative Period | 4 | 2022 | 288 | 0.270 |
Why?
|
Chemoradiotherapy | 2 | 2023 | 67 | 0.250 |
Why?
|
Nasal Septum | 2 | 2023 | 9 | 0.250 |
Why?
|
Case-Control Studies | 2 | 2023 | 638 | 0.250 |
Why?
|
Disease-Free Survival | 4 | 2019 | 175 | 0.240 |
Why?
|
Surgical Flaps | 2 | 2021 | 49 | 0.230 |
Why?
|
Reproducibility of Results | 3 | 2022 | 788 | 0.230 |
Why?
|
Nasal Obstruction | 1 | 2023 | 5 | 0.230 |
Why?
|
Taste Disorders | 2 | 2021 | 5 | 0.230 |
Why?
|
Neurosurgical Procedures | 2 | 2022 | 150 | 0.220 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 6 | 0.220 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2022 | 23 | 0.210 |
Why?
|
Papillomavirus Infections | 1 | 2022 | 37 | 0.210 |
Why?
|
Neoplasm Invasiveness | 3 | 2021 | 68 | 0.210 |
Why?
|
Nasal Lavage | 1 | 2021 | 2 | 0.210 |
Why?
|
Pituitary-Adrenal System | 1 | 2021 | 11 | 0.210 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2021 | 14 | 0.210 |
Why?
|
Skull Base Neoplasms | 1 | 2021 | 15 | 0.210 |
Why?
|
Social Media | 1 | 2022 | 27 | 0.210 |
Why?
|
Fibrosis | 2 | 2018 | 39 | 0.200 |
Why?
|
Hydrocortisone | 1 | 2021 | 43 | 0.200 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2021 | 62 | 0.200 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 75 | 0.200 |
Why?
|
Radiology | 1 | 2021 | 22 | 0.200 |
Why?
|
Chondrosarcoma | 1 | 2021 | 30 | 0.200 |
Why?
|
Gloves, Surgical | 1 | 2021 | 7 | 0.200 |
Why?
|
Air Pollution | 1 | 2021 | 17 | 0.200 |
Why?
|
Neoplasm Seeding | 1 | 2021 | 7 | 0.200 |
Why?
|
Professional Role | 1 | 2021 | 27 | 0.200 |
Why?
|
Air Pollutants | 1 | 2021 | 12 | 0.200 |
Why?
|
Natural Killer T-Cells | 1 | 2020 | 5 | 0.200 |
Why?
|
Surgical Instruments | 1 | 2021 | 25 | 0.200 |
Why?
|
Empty Sella Syndrome | 1 | 2020 | 4 | 0.190 |
Why?
|
Operating Rooms | 1 | 2020 | 14 | 0.190 |
Why?
|
Glottis | 1 | 2020 | 3 | 0.190 |
Why?
|
Observer Variation | 1 | 2021 | 118 | 0.190 |
Why?
|
Anti-Bacterial Agents | 2 | 2016 | 402 | 0.190 |
Why?
|
Hemostatic Techniques | 1 | 2020 | 8 | 0.190 |
Why?
|
Eczema | 1 | 2020 | 4 | 0.190 |
Why?
|
Surgery Department, Hospital | 1 | 2020 | 5 | 0.190 |
Why?
|
Neuroendoscopy | 1 | 2020 | 8 | 0.190 |
Why?
|
Epistaxis | 1 | 2020 | 9 | 0.190 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 2020 | 7 | 0.190 |
Why?
|
Pharynx | 1 | 2020 | 14 | 0.190 |
Why?
|
Urban Health Services | 1 | 2020 | 13 | 0.190 |
Why?
|
Inservice Training | 1 | 2020 | 26 | 0.190 |
Why?
|
Airway Management | 1 | 2020 | 16 | 0.190 |
Why?
|
Microbiota | 2 | 2018 | 105 | 0.190 |
Why?
|
Tracheostomy | 1 | 2020 | 19 | 0.190 |
Why?
|
Education, Nursing, Continuing | 1 | 2020 | 27 | 0.190 |
Why?
|
Cryosurgery | 1 | 2020 | 20 | 0.190 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2020 | 21 | 0.190 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 79 | 0.190 |
Why?
|
Pseudomonas aeruginosa | 2 | 2018 | 79 | 0.190 |
Why?
|
Ambulatory Care | 1 | 2020 | 75 | 0.180 |
Why?
|
Papilloma, Inverted | 1 | 2020 | 14 | 0.180 |
Why?
|
Sella Turcica | 1 | 2019 | 5 | 0.180 |
Why?
|
Surgeons | 1 | 2021 | 76 | 0.180 |
Why?
|
Trachea | 1 | 2020 | 31 | 0.180 |
Why?
|
Surgical Wound | 1 | 2019 | 11 | 0.180 |
Why?
|
Drug-Eluting Stents | 1 | 2019 | 11 | 0.180 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 208 | 0.180 |
Why?
|
Steroids | 1 | 2019 | 22 | 0.180 |
Why?
|
Postoperative Care | 1 | 2020 | 127 | 0.180 |
Why?
|
Food Hypersensitivity | 1 | 2020 | 57 | 0.180 |
Why?
|
Skin | 1 | 2020 | 117 | 0.180 |
Why?
|
Elective Surgical Procedures | 1 | 2019 | 43 | 0.170 |
Why?
|
Craniopharyngioma | 1 | 2018 | 3 | 0.170 |
Why?
|
Sphenoid Bone | 1 | 2018 | 4 | 0.170 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 37 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 340 | 0.170 |
Why?
|
Sweat Gland Neoplasms | 1 | 2018 | 3 | 0.170 |
Why?
|
Bacteroidetes | 1 | 2018 | 4 | 0.170 |
Why?
|
Physicians | 1 | 2020 | 115 | 0.170 |
Why?
|
Firmicutes | 1 | 2018 | 6 | 0.170 |
Why?
|
Mass Screening | 1 | 2020 | 177 | 0.170 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 215 | 0.170 |
Why?
|
Hemostasis, Surgical | 1 | 2018 | 15 | 0.160 |
Why?
|
Fibroma, Ossifying | 1 | 2018 | 5 | 0.160 |
Why?
|
Osteoma | 1 | 2018 | 5 | 0.160 |
Why?
|
Vasoconstrictor Agents | 1 | 2018 | 28 | 0.160 |
Why?
|
Sleep Wake Disorders | 1 | 2020 | 148 | 0.160 |
Why?
|
Self Report | 1 | 2019 | 218 | 0.160 |
Why?
|
Asthma | 1 | 2020 | 138 | 0.160 |
Why?
|
Illinois | 1 | 2019 | 241 | 0.160 |
Why?
|
Time Factors | 2 | 2021 | 1616 | 0.160 |
Why?
|
Epinephrine | 1 | 2018 | 35 | 0.160 |
Why?
|
Diagnostic Errors | 1 | 2018 | 40 | 0.160 |
Why?
|
Clinical Competence | 1 | 2020 | 230 | 0.160 |
Why?
|
Age Distribution | 1 | 2018 | 94 | 0.160 |
Why?
|
Sex Distribution | 1 | 2018 | 87 | 0.160 |
Why?
|
Lymphoma | 1 | 2018 | 44 | 0.160 |
Why?
|
Drugs, Investigational | 1 | 2017 | 8 | 0.160 |
Why?
|
Invasive Fungal Infections | 1 | 2017 | 4 | 0.150 |
Why?
|
Radiation Injuries | 1 | 2017 | 34 | 0.150 |
Why?
|
Frozen Sections | 1 | 2017 | 11 | 0.150 |
Why?
|
Aspergillosis | 1 | 2017 | 10 | 0.150 |
Why?
|
Mucormycosis | 1 | 2017 | 8 | 0.150 |
Why?
|
Parathyroid Glands | 1 | 2017 | 7 | 0.150 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 79 | 0.150 |
Why?
|
Respiratory Function Tests | 1 | 2017 | 32 | 0.150 |
Why?
|
Pseudomonas Infections | 1 | 2017 | 59 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2016 | 71 | 0.150 |
Why?
|
Mucous Membrane | 1 | 2016 | 40 | 0.140 |
Why?
|
Radiopharmaceuticals | 1 | 2016 | 48 | 0.140 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2016 | 39 | 0.140 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 340 | 0.140 |
Why?
|
Neurilemmoma | 1 | 2015 | 13 | 0.140 |
Why?
|
Infant | 3 | 2015 | 531 | 0.140 |
Why?
|
Immunity, Innate | 1 | 2016 | 90 | 0.130 |
Why?
|
Adrenal Cortex Hormones | 1 | 2016 | 100 | 0.130 |
Why?
|
Eye Neoplasms | 1 | 2014 | 5 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 162 | 0.130 |
Why?
|
Tertiary Healthcare | 1 | 2014 | 2 | 0.120 |
Why?
|
Lymphatic Vessels | 1 | 2014 | 6 | 0.120 |
Why?
|
California | 1 | 2014 | 31 | 0.120 |
Why?
|
Elastic Modulus | 1 | 2014 | 12 | 0.120 |
Why?
|
Viscosity | 1 | 2014 | 10 | 0.120 |
Why?
|
Elasticity Imaging Techniques | 1 | 2014 | 8 | 0.120 |
Why?
|
Transducers | 1 | 2014 | 10 | 0.120 |
Why?
|
Lymphocytes | 1 | 2014 | 110 | 0.120 |
Why?
|
Image Enhancement | 1 | 2014 | 57 | 0.120 |
Why?
|
Sex Factors | 3 | 2020 | 496 | 0.120 |
Why?
|
Nontuberculous Mycobacteria | 1 | 2011 | 5 | 0.110 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2011 | 7 | 0.110 |
Why?
|
Multivariate Analysis | 3 | 2019 | 324 | 0.100 |
Why?
|
Lasers, Solid-State | 1 | 2011 | 2 | 0.100 |
Why?
|
Laryngeal Diseases | 1 | 2011 | 3 | 0.100 |
Why?
|
Laser Therapy | 1 | 2011 | 13 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 2011 | 9 | 0.100 |
Why?
|
Immunotherapy | 2 | 2021 | 62 | 0.100 |
Why?
|
Tongue | 2 | 2021 | 8 | 0.100 |
Why?
|
Language Development | 1 | 2010 | 7 | 0.100 |
Why?
|
Otoacoustic Emissions, Spontaneous | 1 | 2010 | 1 | 0.100 |
Why?
|
Hair Cells, Auditory | 1 | 2010 | 2 | 0.100 |
Why?
|
Evoked Potentials, Auditory, Brain Stem | 1 | 2010 | 4 | 0.100 |
Why?
|
Actinomycosis | 1 | 2010 | 3 | 0.100 |
Why?
|
Meningitis, Bacterial | 1 | 2010 | 8 | 0.090 |
Why?
|
Encephalitis | 1 | 2010 | 17 | 0.090 |
Why?
|
Speech Intelligibility | 1 | 2010 | 12 | 0.090 |
Why?
|
Audiometry | 1 | 2010 | 4 | 0.090 |
Why?
|
Deafness | 1 | 2010 | 16 | 0.090 |
Why?
|
Positron Emission Tomography Computed Tomography | 2 | 2022 | 21 | 0.090 |
Why?
|
Analysis of Variance | 1 | 2010 | 321 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 328 | 0.090 |
Why?
|
Comorbidity | 2 | 2020 | 498 | 0.080 |
Why?
|
Logistic Models | 2 | 2021 | 407 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 553 | 0.060 |
Why?
|
Hypertrophy | 1 | 2023 | 19 | 0.060 |
Why?
|
Temperature | 1 | 2023 | 76 | 0.060 |
Why?
|
Surveys and Questionnaires | 2 | 2020 | 1184 | 0.060 |
Why?
|
Papillomaviridae | 1 | 2022 | 29 | 0.050 |
Why?
|
Video Recording | 1 | 2022 | 47 | 0.050 |
Why?
|
Information Dissemination | 1 | 2022 | 23 | 0.050 |
Why?
|
Cerebrospinal Fluid Otorrhea | 1 | 2021 | 5 | 0.050 |
Why?
|
Petrous Bone | 1 | 2021 | 7 | 0.050 |
Why?
|
Length of Stay | 1 | 2023 | 317 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 79 | 0.050 |
Why?
|
Tourette Syndrome | 1 | 2021 | 37 | 0.050 |
Why?
|
Hospitals, Teaching | 1 | 2021 | 33 | 0.050 |
Why?
|
Environmental Exposure | 1 | 2021 | 15 | 0.050 |
Why?
|
Cytological Techniques | 1 | 2021 | 14 | 0.050 |
Why?
|
Particulate Matter | 1 | 2021 | 22 | 0.050 |
Why?
|
Optic Chiasm | 1 | 2020 | 3 | 0.050 |
Why?
|
Optic Nerve | 1 | 2020 | 6 | 0.050 |
Why?
|
Aerosols | 1 | 2020 | 21 | 0.050 |
Why?
|
Biometry | 1 | 2020 | 8 | 0.050 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 21 | 0.050 |
Why?
|
Induction Chemotherapy | 1 | 2020 | 14 | 0.050 |
Why?
|
Genomics | 1 | 2020 | 43 | 0.050 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 42 | 0.050 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 91 | 0.050 |
Why?
|
Perception | 1 | 2020 | 83 | 0.050 |
Why?
|
Clinical Protocols | 1 | 2020 | 65 | 0.050 |
Why?
|
Emergencies | 1 | 2020 | 39 | 0.050 |
Why?
|
Global Health | 1 | 2020 | 55 | 0.050 |
Why?
|
Adenoma | 1 | 2020 | 42 | 0.050 |
Why?
|
Patient Care Planning | 1 | 2020 | 56 | 0.050 |
Why?
|
RNA, Viral | 1 | 2020 | 148 | 0.050 |
Why?
|
Internet | 1 | 2020 | 91 | 0.040 |
Why?
|
Pilot Projects | 1 | 2021 | 394 | 0.040 |
Why?
|
Practice Patterns, Physicians' | 1 | 2020 | 132 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 101 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 218 | 0.040 |
Why?
|
Air | 1 | 2018 | 6 | 0.040 |
Why?
|
Olfactory Bulb | 1 | 2019 | 16 | 0.040 |
Why?
|
Metaplasia | 1 | 2018 | 11 | 0.040 |
Why?
|
Models, Statistical | 1 | 2019 | 132 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 22 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 56 | 0.040 |
Why?
|
Phenotype | 1 | 2019 | 355 | 0.040 |
Why?
|
Patient Selection | 1 | 2020 | 232 | 0.040 |
Why?
|
Prevalence | 1 | 2020 | 487 | 0.040 |
Why?
|
Administration, Topical | 1 | 2018 | 17 | 0.040 |
Why?
|
Biodiversity | 1 | 2018 | 37 | 0.040 |
Why?
|
Cranial Nerve Diseases | 1 | 2017 | 2 | 0.040 |
Why?
|
Necrosis | 1 | 2017 | 26 | 0.040 |
Why?
|
Staphylococcus aureus | 1 | 2018 | 85 | 0.040 |
Why?
|
Basement Membrane | 1 | 2017 | 12 | 0.040 |
Why?
|
Drug Design | 1 | 2017 | 30 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2020 | 295 | 0.040 |
Why?
|
Risk Assessment | 1 | 2020 | 679 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2018 | 86 | 0.040 |
Why?
|
Biopsy | 1 | 2018 | 234 | 0.040 |
Why?
|
Mucor | 1 | 2017 | 4 | 0.040 |
Why?
|
Aspergillus | 1 | 2017 | 7 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2017 | 39 | 0.040 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2017 | 4 | 0.040 |
Why?
|
Edema | 1 | 2017 | 38 | 0.040 |
Why?
|
Ethmoid Bone | 1 | 2016 | 2 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2017 | 45 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 959 | 0.040 |
Why?
|
Acute Disease | 1 | 2017 | 226 | 0.040 |
Why?
|
Disease Progression | 1 | 2018 | 787 | 0.030 |
Why?
|
Animals | 2 | 2017 | 4552 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 333 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 1221 | 0.030 |
Why?
|
Decision Making | 1 | 2017 | 220 | 0.030 |
Why?
|
Biomarkers | 1 | 2017 | 689 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2014 | 106 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2015 | 604 | 0.030 |
Why?
|
Equipment Design | 1 | 2014 | 185 | 0.030 |
Why?
|
Body Mass Index | 1 | 2015 | 428 | 0.030 |
Why?
|
Facial Pain | 1 | 2011 | 5 | 0.030 |
Why?
|
Long-Term Care | 1 | 2011 | 58 | 0.030 |
Why?
|
Granuloma, Laryngeal | 1 | 2011 | 1 | 0.030 |
Why?
|
Leukoplakia | 1 | 2011 | 1 | 0.030 |
Why?
|
Stroboscopy | 1 | 2011 | 1 | 0.030 |
Why?
|
Polyps | 1 | 2011 | 3 | 0.030 |
Why?
|
Laryngeal Edema | 1 | 2011 | 2 | 0.030 |
Why?
|
Cysts | 1 | 2011 | 16 | 0.020 |
Why?
|
Laryngoscopy | 1 | 2011 | 21 | 0.020 |
Why?
|
Superoxide Dismutase-1 | 1 | 2010 | 1 | 0.020 |
Why?
|
Hemorrhage | 1 | 2011 | 75 | 0.020 |
Why?
|
Speech Production Measurement | 1 | 2010 | 2 | 0.020 |
Why?
|
Auditory Threshold | 1 | 2010 | 15 | 0.020 |
Why?
|
Hearing Tests | 1 | 2010 | 9 | 0.020 |
Why?
|
Superoxide Dismutase | 1 | 2010 | 19 | 0.020 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2011 | 74 | 0.020 |
Why?
|
Models, Animal | 1 | 2010 | 126 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2010 | 125 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2010 | 248 | 0.020 |
Why?
|
Facial Asymmetry | 1 | 2009 | 1 | 0.020 |
Why?
|
Esthetics | 1 | 2009 | 9 | 0.020 |
Why?
|
Linear Models | 1 | 2010 | 254 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2010 | 432 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2010 | 502 | 0.020 |
Why?
|
Mice | 1 | 2010 | 1607 | 0.020 |
Why?
|